Evidence map›Paper›PMID 29032710›Full record

ArticleLeukemia & lymphoma2018

Phase I dose escalation study of the anti-CD2 monoclonal antibody, siplizumab, with DA-EPOCH-R in aggressive peripheral T-cell lymphomas.

Joseph Roswarski, Mark Roschewski, Andrea Lucas, Christopher Melani, Stefania Pittaluga, Elaine S Jaffe, Seth M Steinberg, Thomas A Waldmann, Wyndham H Wilson

Registry-linked trialOpen access · greenAbstract readClinical Trial, Phase ILetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia & lymphoma, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01445535 (Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01445535 phase1completednot on this map

Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in T and NK-Cell Lymphomas

TypeinterventionalSponsorNational Cancer Institute (NCI)Ran2009 to 2020Enrolled15ConditionsT-Cell Peripheral Lymphoma, Gamma Delta Hepatosplenic T-Cell Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma, NK T-Cell LymphomaArmsRituximab, Etoposide, Siplizumab, Prednisone, Vincristine
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. CD2 Immunobiology.Frontiers in immunology · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Joseph Roswarskia Center for Cancer Research, National Cancer Institute , Bethesda , MD , USA.ORCID 0000-0002-1470-8814
Mark Roschewskia Center for Cancer Research, National Cancer Institute , Bethesda , MD , USA.
Andrea Lucasa Center for Cancer Research, National Cancer Institute , Bethesda , MD , USA.
Christopher Melania Center for Cancer Research, National Cancer Institute , Bethesda , MD , USA.
Stefania Pittalugac Laboratory of Pathology, National Cancer Institute , Bethesda , MD , USA.
Elaine S Jaffec Laboratory of Pathology, National Cancer Institute , Bethesda , MD , USA.
Seth M Steinberga Center for Cancer Research, National Cancer Institute , Bethesda , MD , USA.
Thomas A Waldmanna Center for Cancer Research, National Cancer Institute , Bethesda , MD , USA.
Wyndham H Wilsona Center for Cancer Research, National Cancer Institute , Bethesda , MD , USA.
National Cancer Institute · USWalter Reed National Military Medical Center · US

Funding

Lymphoma Disease Discovery and DefintionZIASC000550 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI JAFFE, ELAINE · 2009 to 2025
$16.9M
Hematopathology DiagnosisZIABC011070 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI JAFFE, ELAINE · 2009 to 2025
$14.5M
Lymphoma Disease Discovery and DefintionZ01SC000550 · SC · DIVISION OF CLINICAL SCIENCES - NCI · PI JAFFE, ELAINE · 1996 to 2008
$2.3M
Intramural NIH HHS Z01 SC000550
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideDisease ProgressionDoxorubicinEtoposideHumansKaplan-Meier EstimateLymphoma, T-Cell, PeripheralNeoplasm StagingPrednisoneRituximabTreatment OutcomeVincristineAntibodies, Monoclonal, HumanizedCyclophosphamideDoxorubicinEtoposidePrednisoneRituximabsiplizumabVincristine

Identifiers

PMID29032710
PMCPMC6372084
OpenAlexW2766154380

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.